ERAS

Erasca, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes multiple precision oncology programs targeting specific genetic mutations common in various solid tumors, including lung, colorectal, and pancreatic cancers. Erasca's lead programs include ERAS-007, an oral ERK1/2 inhibitor, and naporafenib, a pan-RAF inhibitor being developed for RAS-mutant tumors. The company employs a precision medicine approach, developing therapies designed to target specific molecular alterations in cancer cells. Founded in 2018 and headquartered in San Diego, California, Erasca went public in 2021 through a merger with a special purpose acquisition company (SPAC).